Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.

Journal of managed care & specialty pharmacy - 1 Jul 2018

Pham Timothy T, Keast Shellie L, Farmer Kevin C, Thompson David M, Rathbun R Chris, Nesser Nancy J, Holderread Bethany P, Skrepnek Grant H

Abstract excerpt

BACKGROUND: Outcomes involving newer direct-acting antiviral (DAA) hepatitis C virus (HCV) regimens have not been studied extensively among the Medicaid population. OBJECTIVE: To assess clinical (treatment failure) and economic outcomes for chronic HCV-infected Oklahoma Medicaid members following treatment with DAAs and to measure associations with patient, treatment, and clinical characteristics. METHODS: This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cost of Illness

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Costs

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Liver Cirrhosis

Share to Sustained Virologic Response

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 29952711
DOI: 10.18553/jmcp.2018.24.7.664
PMCID: PMC10398076

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.PMID 29952711Read ↗

Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.Semantic proximity Read ↗

Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.Semantic proximity Read ↗

Real-world value of direct-acting antivirals for hepatitis C at Kaiser Permanente Southern California.Semantic proximity Read ↗

Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.Semantic proximity Read ↗

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.Semantic proximity Read ↗

Cost effectiveness of hepatitis C direct acting agents.Semantic proximity Read ↗

The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.Semantic proximity Read ↗

Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy: A National Observational Cohort StudySemantic proximity Read ↗

Challenges of hepatitis C treatment in Native Americans in two North Dakota medical facilities.Semantic proximity Read ↗

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read ↗

Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.Semantic proximity Read ↗

Treatment Failure with Direct Antiviral Agents in Patients with Hepatitis C Virus Genotype 1 Infection at the Veteran Affairs Caribbean Healthcare System in San Juan, Puerto Rico.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.